Note: the documents on this web site are PDF files. If you do not have a PDF reader, you can download one now.

Product name Product type Date released
Expand Azopt CMI 26 Jul 2017
 
Azopt Eye Drops contain the active ingredient brinzolamide, which belongs to a class of medicines known as "carbonic anhydrase inhibitors".
Azopt Eye Drops are used, either alone or in combination with other eye drops/medicines, to lower raised pressure in the eye and to treat glaucoma.
Glaucoma is a condition in which the pressure of fluid in the eye may be high. However, some people with glaucoma may have normal eye pressure.
Glaucoma is usually caused by a build up of the fluid which flows through the eye. This build up occurs because the fluid drains out of the eye more slowly than it is being pumped in. Since new fluid continues to enter the eye, joining the fluid already there, the pressure continues to rise. This raised pressure may damage the back of the eye resulting in gradual loss of sight. Damage can progress so slowly that the person is not aware of this gradual loss of sight. Sometimes even normal eye pressure is associated with damage to the back of the eye.
There are usually no symptoms of glaucoma. The only way of knowing that you have glaucoma is to have your eye pressure, optic nerve and visual field checked by an eye specialist or optometrist. If glaucoma is not treated, it can lead to serious problems, including total blindness. In fact, untreated glaucoma is one of the most common causes of blindness.
Azopt Eye Drops lower the pressure within the eye by reducing the production of fluid.
Although Azopt Eye Drops help to control your glaucoma, they do not cure it.
For more information about glaucoma, contact Glaucoma Australia Inc. (PO BOX 420, Crows Nest 1585 telephone 1800 500 880).
Ask your doctor if you have any questions about why Azopt has been prescribed for you.
Your doctor may have prescribed it for another reason.
This medicine is only available with a doctor's prescription.
Azopt Eye Drops are not addictive.
Use in Children
Azopt Eye Drops are not recommended for use in children. The safety and effectiveness of Azopt Eye Drops in children has not been established.
read more
Expand Rhinocort Hayfever PI 24 Jul 2017
 
Expand Rhinocort Hayfever CMI 24 Jul 2017
 
Expand APO-Fluoxetine CMI 21 Jul 2017
 
The name of your medicine is APO-Fluoxetine It contains the active ingredient fluoxetine (as fluoxetine hydrochloride).
It is used to treat:
depression
obsessive compulsive disorder (OCD).
Ask your doctor if you have any questions about why this medicine has been prescribed for you. Your doctor may have prescribed this medicine for another reason.
This medicine is available only with a doctor's prescription.

How it works

Fluoxetine belongs to a group of medicines called selective serotonin reuptake inhibitors (SSRIs). Serotonin is one of the chemicals in your brain which helps control your mood. Fluoxetine and other SSRIs are thought to help by increasing the amount of serotonin in your brain.
Depression is longer lasting and/or more severe than the 'low moods' everyone has from time to time due to the stress of everyday life. It is thought to be caused by a chemical imbalance in parts of the brain. This imbalance affects your whole body and can cause emotional and physical symptoms such as feeling low in spirit, loss of interest in activities, being unable to enjoy life, poor appetite or overeating, disturbed sleep, often waking up early, loss of sex drive, lack of energy and feeling guilty over nothing. Fluoxetine corrects this chemical imbalance and may help relieve the symptoms of depression.
Check with your doctor if you need more information about obsessive compulsive disorder (OCD).
The symptoms of OCD vary from patient to patient.
This medicine is not expected to affect your ability to drive a car or operate machinery, but make sure you know how it affects you beforehand, as it can make some people dizzy or drowsy, and affect judgement, thinking and motor skills.

Use in children

Fluoxetine is not recommended for use in children and adolescents under 18 years of age.
read more
Expand APO-Fluoxetine PI 21 Jul 2017
 
Expand APO-Pregabalin CMI 20 Jul 2017
 
The name of your medicine is APO-Pregabalin. It contains the active ingredient pregabalin.
It is used to:
treat neuropathic pain, which is pain caused by an abnormality of, or damage to, the nerves
control epilepsy. Epilepsy is a condition where you have repeated seizures (fits). There are many different types of seizures, ranging from mild to severe.
Pregabalin may be used alone, or in combination with other medicines, to treat your condition.
Your doctor may prescribe pregabalin in addition to your current therapy when your current treatment is no longer working as well as before.
Ask your doctor if you have any questions about why this medicine has been prescribed for you. Your doctor may have prescribed this medicine for another reason.
This medicine is available only with a doctor's prescription.

How it works

Pregabalin belongs to a group of medicines called anticonvulsants. These drugs are thought to work by controlling brain chemicals which send signals to nerves so that seizures do not happen.
Pregabalin also has analgesic effects (relieves pain).

Use in children

There is not enough information to recommend the use of this medicine in children under the age of 18 years.
read more
Expand APO-Pregabalin PI 20 Jul 2017
 
Expand Zaditen PI 17 Jul 2017
 
Expand Ocrevus CMI 17 Jul 2017
 
OCREVUS contains an active ingredient called ocrelizumab.
OCREVUS is used to treat relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
OCREVUS decreases the number of flare-ups (relapses) and slows the worsening of RMS.
OCREVUS also slows the worsening of PPMS.
In MS (multiple sclerosis) your immune system mistakenly attacks the protective layer (myelin) around your nerve cells. This causes inflammation and damage which stops your nervous system working properly.
OCREVUS works on your immune system so that it may reduce the inflammation and attacks on your nervous system reducing the chance of a flare-up and slowing the worsening of your disease.
Your doctor, however, may have prescribed OCREVUS for another purpose.
Ask your doctor if you have any questions about why OCREVUS has been prescribed for you.
This medicine is available only with a doctor's prescription.
This medicine is not addictive.
read more
Expand Ocrevus PI 14 Jul 2017
 
Expand Azopt PI 11 Jul 2017
 
Expand Mepreze CMI 10 Jul 2017
 
MEPREZE is used for the relief of frequent heartburn and stomach acid complaints due to gastro-oesophageal reflux disease (GORD). This can be caused by "washing back" (reflux) of food and acid from the stomach into the food pipe (oesophagus).
Reflux can cause a burning sensation in the chest rising up to the throat, also known as heartburn.
Frequent heartburn is when you have heartburn for two or more times a week. Heartburn that occurs frequently is a typical symptom of GORD.
Who should use MEPREZE
MEPREZE is recommended for adults 18 years of age and over, who suffer from frequent heartburn at least 2 times a week.
MEPREZE is not the right medicine for you if you suffer heartburn only occasionally (one episode of heartburn a week or less), or if you want immediate relief of heartburn.

How MEPREZE works

MEPREZE is a type of medicine called a proton-pump inhibitor. It works by decreasing the amount of acid made by the stomach. This gives relief of symptoms and also allows healing to take place. This does not stop food being digested in the normal way.
MEPREZE is available only from your pharmacist. It can be purchased directly from your local pharmacy without a doctor's prescription.
There is no evidence that this medicine is addictive.
read more
  • Download PDF Standard Print
  • Download PDF Large Print
Expand Mepreze PI 10 Jul 2017
 
Expand Alcaine PI 10 Jul 2017
 
Expand Azarga PI 10 Jul 2017
 
Expand Cyclogyl PI 10 Jul 2017
 
Expand Betoquin PI 10 Jul 2017
 
Expand Betoptic PI 10 Jul 2017
 
Expand Brinzoquin PI 10 Jul 2017
 
Expand Flarex PI 10 Jul 2017